← Leaderboards
Eleftherios Mylonakis
Massachusetts Eye And Ear Infirmary
$8,947,513
Attributed
$8,947,513
Total exposure
8
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $3M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$27,382,665 · 10
By mechanism
P01$15,083,743 · 4
P20$9,300,232 · 2
R01$2,136,742 · 2
R21$483,678 · 1
K08$378,270 · 1
Top collaborators
- Frederick M Ausubel5 shared
- Michael S. Gilmore5 shared
- David C Hooper5 shared
- Roberto G. Kolter5 shared
- Richard Marc Losick5 shared
- Suzanne L. Walker5 shared
Most similar at Massachusetts Eye And Ear Infirmary
Same institution · by research overlap
- David C Hooper$18,131,941
Others in their field
Top investigators on “Infection”
- Wafaa M. El-Sadr · Columbia University Health Sciences$965,939,185
- Lawrence Corey · Fred Hutchinson Cancer Center$789,608,171
- Judith S. Currier · University Of California Los Angeles$511,038,212
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$463,711,983
- Richard Marlink · Elizabeth Glaser Pediatric Aids Fdn$457,210,249
- Joseph J. Eron · Univ Of North Carolina Chapel Hill$415,229,497
Research focus
InfectionCaenorhabditis ElegansProgramsIn VitroBaseToxic EffectAntibiotic ResistanceIn VivoPathogenResearch PersonnelCellsCollaborationsLibrariesDesignDrug DiscoveryPathogenesisAnimalsLeadNovel StrategiesResistanceMicrobial BiofilmsMolecularCombatAntibiotics
Grant awards (32)
Subproject 2: Identification of Pathways that Can be Targeted for the Development of Novel Therapies for MRSA$446,256
P01 · FY2025 · AI · contact PI
Natural Phenolic Compounds against Oral Candidiasis (OC)$401,021
R01 · FY2025 · AI · contact PI
Natural Phenolic Compounds against Oral Candidiasis (OC)$416,396
R01 · FY2024 · AI · contact PI
Subproject 2: Identification of Pathways that Can be Targeted for the Development of Novel Therapies for MRSA$401,498
P01 · FY2024 · AI · contact PI
Subproject 2: Identification of Pathways that Can be Targeted for the Development of Novel Therapies for MRSA$372,500
P01 · FY2023 · AI · contact PI
Subproject 2: Identification of Pathways that Can be Targeted for the Development of Novel Therapies for MRSA$427,167
P01 · FY2022 · AI · contact PI
COBRE Center for Antimicrobial Resistance and Therapeutic Discovery$1,858,738
P20 · FY2021 · GM · contact PI
COBRE Center for Antimicrobial Resistance and Therapeutic Discovery - Administrative Core$456,784
P20 · FY2021 · GM · contact PI
COBRE Center for Antimicrobial Resistance and Therapeutic Discovery$1,900,857
P20 · FY2020 · GM · contact PI
COBRE Center for Antimicrobial Resistance and Therapeutic Discovery - Administrative Core$371,817
P20 · FY2020 · GM · contact PI
COBRE Center for Antimicrobial Resistance and Therapeutic Discovery$1,929,581
P20 · FY2019 · GM · contact PI
COBRE Center for Antimicrobial Resistance and Therapeutic Discovery - Administrative Core$480,333
P20 · FY2019 · GM · contact PI
COBRE Center for Antimicrobial Resistance and Therapeutic Discovery$1,923,357
P20 · FY2018 · GM · contact PI
COBRE Center for Antimicrobial Resistance and Therapeutic Discovery - Administrative Core$378,765
P20 · FY2018 · GM · contact PI
Harvard-wide Program on Antibiotic Resistance$2,158,199
P01 · FY2015 · AI
Identification of Pathways that can be Targeted for the Development of Novel Therapies for MRSA$529,903
P01 · FY2015 · AI · contact PI
Harvard-wide Program on Antibiotic Resistance$2,158,199
P01 · FY2014 · AI
Identification of Pathways that can be Targeted for the Development of Novel Therapies for MRSA$475,797
P01 · FY2014 · AI · contact PI
Harvard-wide Program on Antibiotic Resistance$2,028,707
P01 · FY2013 · AI
ID. of Pathways that can be Targeted for the Develop. of Novel Therapies for MRSA$447,247
P01 · FY2013 · AI · contact PI
Harvard-wide Program on Antibiotic Resistance$2,310,720
P01 · FY2012 · AI
ID. of Pathways that can be Targeted for the Develop. of Novel Therapies for MRSA$665,993
P01 · FY2012 · AI · contact PI
Harvard-wide Program on Antibiotic Resistance$2,166,794
P01 · FY2011 · AI
ID. of Pathways that can be Targeted for the Develop. of Novel Therapies for MRSA$494,763
P01 · FY2011 · AI · contact PI
A C.elegans high-throughput assay for the identification of new antifungal agents$438,075
R01 · FY2010 · AI · contact PI
Genome-wide investigations in fungal pathogens utilizing an invertebrate model ho$262,845
R21 · FY2010 · AI · contact PI
A C.elegans high-throughput assay for the identification of new antifungal agents$441,875
R01 · FY2009 · AI · contact PI
Genome-wide investigations in fungal pathogens utilizing an invertebrate model ho$220,833
R21 · FY2009 · AI · contact PI
A C.elegans high-throughput assay for the identification of new antifungal agents$439,375
R01 · FY2008 · AI · contact PI
C.elegans as a model system forC.neoformans pathogenesis$126,900
K08 · FY2007 · AI · contact PI
C.elegans as a model system forC.neoformans pathogenesis$126,090
K08 · FY2006 · AI · contact PI
C.elegans as a model system forC.neoformans pathogenesis$125,280
K08 · FY2005 · AI